PLx Pharma Inc. Files New Drug Application With FDA and Adds New Board Member

Published: May 23, 2012

HOUSTON--(BUSINESS WIRE)--PLx Pharma Inc., a specialty pharmaceutical company developing a novel aspirin and lipid complex (PL2200 Aspirin 325 mg), reports that the United States Food and Drug Administration (FDA) has accepted for review a new drug application (NDA) for PL2200 Aspirin 325 mg, and the company has elected Peter Mann to its Board of Directors.

Back to news